Flyworks is developing a highly-efficient, fully-autonomous drug screening platform. In our platform, we take genetically-engineered fruit flies (with homologs of 75% of disease-causing human genes) as patient models and unlock their full potential using advanced optics, microfluidics, and reinforcement learning. We expect this platform can dramatically reduce the cost, labor, and time required to screen drug candidates, compared to conventional methods of animal testing. Our platform represents significant economic opportunity in new drug discovery, for established and startup pharmaceutical companies alike. We are interested in making connections, getting feedback on our business model, and discussing funding opportunities for the early stages of our company.